

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

**Respiratory syncytial virus-specific immunoglobulin G (IgG)
concentrations associate with environmental and genetic factors: the
Factors Influencing Pediatric Asthma Study.**

Esther Erdei^{1¶}, Dara Torgerson^{2,3¶}, Rae O'Leary⁴, Melissa Spear^{2,3}, Matias Shedden¹,
Marcia O'Leary⁴, Kendra Enright⁴, Lyle Best^{4, 5}

¹ University of New Mexico Health Sciences Center College of Pharmacy, Albuquerque, NM, USA

² Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA

³ Department of Human Genetics, McGill University, Montreal, QC, Canada

⁴ Missouri Breaks Industries Research Inc, Eagle Butte, SD, USA

⁵ Turtle Mountain Community College, Belcourt, ND, USA

* Corresponding author

E-mail: lbest@restel.com (LGB)

¶These authors contributed equally to this work.

23 Abstract

24 Exposure to respiratory syncytial virus (RSV) during childhood is nearly ubiquitous by
25 age two, and infants who develop severe RSV bronchiolitis are more likely to develop
26 asthma later in life. In the Factors Influencing Pediatric Asthma (FIPA) study including
27 319 children from a Northern Plains American Indian community, we found 73% of
28 children to have high concentrations of RSV-specific IgG (>40 IU/mL). High
29 concentration of RSV-specific IgG was associated with increased exposure to second-
30 hand tobacco smoke ($p=7.5 \times 10^{-4}$), larger household size ($p=4.0 \times 10^{-3}$), and lower levels
31 of total serum IgE ($p=5.1 \times 10^{-3}$). Parents of children with asthma more often reported an
32 RSV diagnosis and/or hospitalization due to RSV, and children with asthma had lower
33 concentrations of RSV IgG as compared to those without asthma among RSV-exposed
34 individuals (mean 117 IU/mL vs. 154, $p=7.1 \times 10^{-4}$). However, lower RSV IgG was
35 surprisingly exclusive to children with asthma recruited during the winter months when
36 RSV is thought to circulate more broadly. Multivariate regression indicated the strongest
37 predictors of RSV-specific IgG concentration included asthma status ($p=0.040$), per cent
38 eosinophils ($p=0.035$), and an asthma x RSV season interaction ($p=3.7 \times 10^{-3}$). Among
39 candidate genes, we identified a genetic association between an intronic variant in
40 *IFNL4* and RSV-specific IgG concentration whereby the minor allele (A) was associated
41 with higher concentration (rs12979860, $p=4.3 \times 10^{-3}$). Overall our findings suggest there
42 are seasonal differences in immunological response to RSV infection in asthma cases
43 vs. controls, and identify both environmental and genetic contributions that warrant
44 further investigation.

45 Introduction

46 Respiratory syncytial virus (RSV) is an RNA virus, classified as a member of the
47 Paramyxoviridae family of negative-strand RNA viruses in the order Mononegavirales. It
48 is the most common cause of bronchiolitis in infants during the first 2-3 years of life [1].
49 Infection by the human RSV orthopneumovirus is ubiquitous, affecting nearly all children
50 by two years of age worldwide [1]. The incidence of hospitalization for bronchiolitis in
51 European and American populations is about 30 per 1,000 in the first year of life [2,3].
52 Ethnic differences in incidence are noted in the United States, with increased risk
53 among Hispanic and American Indian populations [4,5]. Severe RSV infection as an
54 infant confers increased susceptibility to asthma [6–8] and perhaps atopy [6], within at
55 least the subsequent two decades of life. There is also evidence of impaired lung
56 function among young adults with viral bronchiolitis as infants [9]. Almost all infectious
57 agents are involved in complex interactions within their host, and this seems especially
58 true for RSV infection and sequelae. There is evidence that host genetic factors
59 influence the initial pathogenesis of RSV infection [10–13], and that the development of
60 asthma following severe RSV infection is likely due to both genetic [11] and
61 environmental [14] contributions. However, the relationship between immunological
62 response to RSV infection and asthma remains largely unexplored.

63 In spite of pervasive childhood infection and persisting IgG antibodies to RSV in
64 adulthood [15,16], recurrent RSV infection among adults is relatively common [17–19]
65 and a cause of significant morbidity [20,21]. In Tribal community settings, where
66 multigenerational households are common, understanding RSV infection burden from
67 infancy to adulthood is especially important to design preventions and protect

68 community health. The Factors Influencing Pediatric Asthma (FIPA) study [22] enrolled
69 324 children from a Northern Plains American Indian community to characterize the
70 environmental, social and genetic factors associated with asthma in this high-risk, high-
71 prevalence community. The goal of the present analysis was to quantify the
72 immunoglobulin G response to RSV infection in American Indian children with and
73 without asthma, and to investigate the environmental, clinical, and genetic factors that
74 associate with varying response.

75

76 **Methods**

77

78 **Ethics approval and consent to participate**

79 The research protocol was approved by the institutional review boards at the
80 Collaborative Research Center for American Indian Health, Sanford Research, Sioux
81 Falls, SD; the Great Plains Indian Health Service IRB, Aberdeen, SD and the local
82 Tribal government. All participants' parents gave informed consent in writing and all
83 children provided assent.

84

85 **Study population**

86 The Factors Influencing Pediatric Asthma (FIPA) study, enrolled 324 participants
87 from a single site in a population-based, case/control study as previously described [22],

88 of which 319 were included in the current study. Briefly, 108 asthma cases were
89 ascertained by a global search of Indian Health Service electronic medical records for a
90 diagnosis related to asthma (ICD codes 493.00 through 493.92, plus 786.07 [wheezing]
91 and V17.5 [family history of asthma]), and more specifically defined by at least 2 of 3
92 potential criteria (asthma diagnosis, at least 2 prescriptions for bronchodilator
93 medications within the past 2 years, or pulmonary function testing showing a 20%
94 improvement in FEV1 post bronchodilator treatment). Participating children were
95 between 6 and 17 years of age, and two asthma controls were recruited for every
96 asthma case. Cases were individually age-matched (within 6 months, N=216) to control
97 children who did not meet case criteria, primarily by a similar search of electronic
98 medical records.

99 Of 319 participants, 15 indicated their child was born prior to 36 weeks
100 gestational age including 6 asthma cases and 9 asthma controls (minimum reported
101 gestational age of 32 weeks, ranging from 32 – 35 weeks). Palivizumab may in some
102 cases be administered in the NICU to infants born prematurely to provide
103 immunoprophylaxis against RSV, which may alter immunological response to RSV
104 infection. However, we were unable to query NICU records to obtain this information,
105 and parents were not specifically asked whether their child had ever received
106 Palivizumab in infancy.

107 **Study procedures**

108 Parents of potential participants were contacted by study field assistants via
109 telephone and invited to participate if eligibility criteria were met. Parents of all

110 participants completed a standardized questionnaire related to socio-demographic,
111 housing environment and health history of their children. Two questions related to prior
112 RSV infections were asked, including “Has a medical person ever said that your child
113 had RSV? Yes or No.”, and “Has your child ever had to stay overnight in the hospital?
114 Yes or No.”. If they responded yes to prior hospitalization, parents were asked to fill in
115 the “Reason/Diagnosis”, and “Age”. From these questions, we generated two variables
116 related to clinical manifestation of RSV infection, including self-reported “RSV infection”
117 and “RSV hospitalization”.

118 At baseline, all children were examined for anthropometric measures, pulmonary
119 function testing, and home environmental sampling. The following laboratory samples
120 were obtained: (1) Blood was collected to perform basic measures of immune status
121 including % eosinophils, RSV IgG, total serum IgE, and C-reactive protein (CRP), 2)
122 salivary DNA samples (Oragene OGR-500, DNA Genotek, Ottawa, Canada) were
123 collected for DNA genotyping, following manufacturer approved extraction, and (3)
124 salivary cotinine samples (Accutest, NicAlert, Encino, California) were collected to
125 measure exposure to tobacco products in the past 48 hours. A follow-up exam
126 approximately 3 years later, repeated pulmonary function testing and collected
127 additional biological samples for ancillary testing as described above.

128

129 **Laboratory measurements**

130 **RSV-specific IgG serum antibody concentrations** were determined
131 on 319 participants, using stored serum collected at either baseline (1st exam, or study

132 entry, N=48) or at follow-up (2nd exam, N=271). RSV IgG serum concentration was
133 quantified using an IBL International certified sandwich ELISA assay (Hamburg,
134 Germany, catalogue number: RE RE56881-10, Lot#: RG-204). Each serum sample
135 was diluted 1:100 times before use, and 100 µL of each Standard solution (A-D) and
136 diluted sample were added to the RSV antigen pre-coated wells of the microtiter plate.
137 The process followed the protocol provided by the company and quality control
138 standards were included and assured at each run. Optical density (OD) was measured
139 with a spectrophotometer at 450 nm (Reference-wavelength: 600-650 nm) within 60 min
140 after pipetting of the stop solution. Standard curve point-to-point analysis method was
141 applied for each plate and run to determine RSV-specific IgG concentrations (IU/ml) for
142 each participant's serum sample.

143 **Measurement of high sensitivity C-reactive protein (CRP)** in serum
144 was done at Sanford Laboratories, Rapid City, SD, using a particle enhanced
145 immunoturbidimetric assay (Roche dedicated CRPHS reagent, catalog number
146 04628918190, Roche Diagnostics, Indianapolis, IN), on a Roche Cobas 6000
147 instrument using the manufacturer's recommended protocols.

148 **Total IgE** determinations were also carried out by Sanford Laboratories, (Sioux
149 Falls, SD) using fluorescent enzyme immunoassays for each antigen, (ImmunoCAP
150 dedicated reagents, catalog number 10-9319-01, Phadia AB, Uppsala, Sweden) on the
151 Phadia ImmunoCAP 250 instrument.

152 **Complete blood count**, including eosinophil and other specific cells, was
153 measured on a SYSMEX XNL-450 hematology analyzer (Lincolnshire, IL) at the local

154 hospital within hours of phlebotomy, using reagents and quality controls as specified by
155 the manufacturer.

156 **Salivary cotinine** measures were obtained using the Accutest NicAlert™
157 (Jant Pharmacal Corp, Encino, CA) with visual comparison to a standard strip resulting
158 in 0-7 ordinal levels.

159 **Genome-wide SNP genotyping** was performed for 2.5 million variants on
160 the expanded multi-ethnic genotyping array (MEGA^{EX} array, Illumina Inc.), with standard
161 variant calling and quality control measures applied (genotyping rate > 95%, Hardy-
162 Weinberg $p > 0.0001$, tests for unexpected relatedness/duplication between samples).
163 The present study examined 11 selected variants related to clinical RSV outcomes.
164 These additional measures were consistent with the participants' consents and
165 approved by Tribal authorities.

166

167 **Statistical analysis**

168 Statistical analyses were performed using R [23]. Contrasts of the clinical
169 characteristics of asthma cases vs. controls, study participants with high IgG (>40 IU/ml)
170 vs. low/undetected IgG (<40 IU/ml), and individuals with asthma reporting asthma
171 medication usage were performed using a student's t-test. Multi-variable linear
172 regression was used to evaluate the correlation between serum RSV- specific IgG
173 concentrations (IU/ml) and asthma, household size at study entry, body mass index

174 (BMI), gender, acute exposure to tobacco (using saliva cotinine determinations), serum
175 concentration of CRP, age, total IgE, and % eosinophils in whole blood.

176 The effect of seasonality on RSV-specific IgG concentration was also evaluated
177 by generating a binary variable for serum samples collected during periods of potentially
178 higher RSV transmission (December – April) vs. lower RSV transmission (May –
179 November), at either the baseline or follow-up visit. Tests of genetic association with 11
180 candidate variants selected from the literature potentially associated with RSV immune
181 or clinical response were performed using linear regression, adjusting for asthma, age,
182 and sex. Values of RSV-specific IgG concentration that were below assay detection
183 (left-censored) were transformed using $1/\sqrt{2}$ (N=11 samples) prior to association testing.

184

185 Results

186

187 Quantitative measurements of serum RSV IgG were obtained among 108
188 individuals with asthma, and 211 individuals without asthma (total N = 319). Clinical and
189 demographic characteristics of asthma cases and controls are summarized in Table 1.
190 At study entry, mean age, % male gender, and levels of C-reactive protein (CRP) were
191 not significantly different between asthma cases and controls. However, individuals with
192 asthma had a significantly smaller household size at baseline as compared to asthma
193 controls. (Table 1; $p=1.6 \times 10^{-4}$). Asthma cases also had higher levels of total serum IgE
194 as compared to asthma controls (Table 1, $p=3.1 \times 10^{-5}$), and a non-significant trend

195 towards having higher BMI (p=0.054). The geometric mean of total IgE was 111 and
 196 53% of children were above the clinical upper limit of normal (100 kU/L).

197

198 **Table 1. Clinical characteristics of asthma cases and controls with measured**
 199 **serum RSV IgG in the Factors Influencing Pediatric Asthma study (FIPA).**

	Asthma Cases	Asthma Controls	P-value
N	108	211	-
Age at Enrollment (mean)	11.8	12.2	0.32
Gender (% male)	52.8	50.7	0.81
BMI (mean)	25.4	23.7	0.054
Cotinine (NicAlert, mean)	0.99	1.17	0.098
Household Size at Enrollment (mean)	5.3	6.3	1.6x10 ^{-4a}
Undetected (IgG<10 IU/mL, N)	0	26	1.6x10 ^{-5a}
High IgG (IgG > 40 IU/mL, %)	61.1	80.6	2.6x10 ^{-4a}
RSV IgG (IU/mL, mean)	117	135	0.093
RSV IgG (IU/mL, mean, excluding undetected)	117	154	7.1x10 ^{-4a}
Hospitalizations from RSV (%)	17.6%	6.7%	0.00358 ^a
RSV diagnosis (%)	34.6%	16.1%	4.5x10 ^{-4a}
Total Serum IgE [log (kU/L), mean]	5.2	4.4	3.1x10 ^{-5a}
% Eosinophils (mean)	5.0	3.8	0.0098
CRP (log, mean)	0.16	0.0050	0.22

200 ^aStatistically significant following Bonferroni adjustment for 14 tests (p < 3.66x10⁻³).

201

202 The majority of individuals were classified as having high RSV-specific IgG
 203 concentrations (N=236, or 73%), which was defined as being above 40 IU/ml threshold
 204 by validation against the WHO standard per company protocol. A total of 26 individuals
 205 had RSV-specific IgG concentrations < 10 IU/ml, indicating either no prior
 206 infection/exposure to RSV or an impaired humoral response. All of these individuals
 207 were asthma controls. To confirm the quality of the 26 serum samples where no or low
 208 RSV IgG levels were detected, we measured vaccination-induced IgG concentrations

209 against measles, pertussis, and tetanus antigens (IBL International detection kits used).
210 All samples had measurable concentrations expressed as IU/ml values, providing
211 additional evidence these samples were of high quality and reflect reliable measures of
212 no/low RSV-specific IgG. Furthermore, we found vaccine-induced IgG concentrations
213 were not significantly different in individuals with low/no RSV IgG as compared to 17
214 individuals with RSV IgG concentrations > 10 IU/ml (S1 Fig). Characteristics of
215 individuals with high as compared to low concentration of RSV-specific IgG are
216 presented in Table 2, which include higher levels of cotinine ($p=8.6 \times 10^{-4}$), larger
217 household sizes at enrollment ($p=4.0 \times 10^{-3}$), and lower levels of total serum IgE
218 ($p=5.1 \times 10^{-3}$).

219

220 **Table 2. Comparison of individuals with high RSV IgG (>40 IU/ml vs. low (<40**
221 **IU/ml).**

	High IgG	Low IgG	P-value
N	236	83	-
Age at Enrollment (mean)	12.1	11.8	0.38
Gender (% male)	50.4	54.2	0.61
BMI (mean)	24.1	24.7	0.46
Cotinine (NicAlert, mean)	1.20	0.855	7.5×10^{-4a}
Household Size at Enrollment (mean)	6.2	5.4	4.0×10^{-3a}
Total Serum IgE [log (kU/L), mean]	4.57	5.12	5.1×10^{-3a}
CRP (log, mean)	0.33	0.27	0.65

222 ^aStatistically significant following Bonferroni correction for 7 tests ($p < 7.1 \times 10^{-3}$)

223

224 In our contrasts of individual variables, we found asthma cases had significantly
225 lower serum RSV-specific IgG concentrations as compared to asthma controls among
226 exposed individuals ($p=7.1 \times 10^{-4}$, Table 1). Parents/guardians of asthma cases were

227 more likely to report their child had been previously diagnosed with RSV by a healthcare
228 professional as compared to parents/guardians of asthma controls (34.6% vs. 16.1%
229 respectively, $p=4.5 \times 10^{-4}$), more likely to report hospitalization due to RSV infection
230 (17.6% for asthma cases vs. 6.7% for asthma controls, $p=0.0036$).

231 Asthma cases recruited during typical RSV season (December – April) had
232 significantly lower total RSV-specific IgG as compared to asthma cases recruited
233 outside of RSV season (May – November), and as compared to asthma controls
234 regardless of RSV season (Fig 1). However, apart from RSV-specific IgG
235 concentrations, we found no differences in the clinical and demographic variables
236 between asthma cases recruited during vs. outside of RSV season (Table 3). In
237 contrast, asthma controls had similar levels of RSV IgG irrespective of the season they
238 were recruited in. In our multi-variate regression model, variables that were associated
239 with RSV-specific IgG were limited to asthma, % of blood eosinophils, and the
240 interaction between asthma x RSV season (Table 4).

241

242 **Figure 1. Boxplot showing the distribution of serum RSV IgG in asthma cases vs.**
243 **controls, stratified by RSV season. Asthma cases recruited during RSV season**
244 **(Dec – April) have significantly lower RSV IgG as compared to asthma cases**
245 **recruited outside RSV season (May – Nov) (t-test, $p=2.5 \times 10^{-6}$). There was no**
246 **observed difference in seasonality for asthma controls ($p=0.60$).**

247

248 **Table 3. Clinical characteristics of asthma cases recruited during the**
 249 **winter/spring (December through April) when RSV is typically circulating more**
 250 **broadly in the community vs. the summer/fall (May through November).**

	Winter/Spring	Summer/Fall	P-value
N	54	54	-
Age at Enrollment (mean)	12.0	11.6	0.53
Gender (% male)	53.7	51.9	1.0
BMI (mean)	26.0	24.9	0.47
Cotinine (NicAlert, mean)	0.85	1.1	0.13
Household Size at Enrollment (mean)	5.0	5.6	0.13
Undetected (IgG<10 IU/mL, N)	0	0	1.0
High IgG (IgG > 40 IU/mL, %)	37.0	85.2	4.3x10 ^{-7a}
RSV IgG (IU/mL, mean)	75.8	157	2.5x10 ^{-6a}
Hospitalizations from RSV (%)	18.5%	16.7%	1.0
RSV diagnosis (%)	33.3%	35.8%	0.84
Total Serum IgE [log (kU/L), mean]	5.3	5.1	0.53
% Eosinophils (mean)	4.9	5.1	0.80
CRP (log, mean)	0.038	0.38	0.26

251 ^aStatistically significant following Bonferroni adjustment for 14 comparisons ($p < 3.9 \times 10^{-3}$).

252

253 **Table 4. Results of multiple linear regression for total serum RSV IgG**
 254 **concentrations.**

	Estimate	Standard Error	Test Statistic	P-value
Asthma	29.8	14.4	2.07	0.0398 ^a
Household size	3.32	2.45	1.36	0.176
lnBMI	-2.49	24.5	-0.102	0.919
Gender	-4.13	10.2	-0.407	0.684
Cotinine (NicAlert)	6.76	5.90	1.15	0.253
lnCRP	-4.44	5.76	-0.770	0.442
age	-1.83	1.90	-0.959	0.339
RSV season	-9.47	15.5	-0.610	0.542
Total IgE	0.00108	0.00964	0.112	0.911
% Eosinophils	-3.42	1.61	-2.12	0.0350 ^a
Asthma x RSV season (interaction)	-68.0	23.2	-2.92	0.00373 ^b

255 ^a $p < 0.05$

256 ^b $p < 0.01$

257

258 Among 11 candidate variants selected from the literature to have potential effects
259 on RSV infection, we identified a significant genetic association with an intronic variant
260 in *IFNL4* (Interferon Lambda 4, Table 5).

261

262 **Table 5. Results of genetic association at candidate variants with total serum RSV IgG concentration in 276**
 263 **unrelated children with and without asthma. Tests for association were adjusted for asthma, age, and sex.**

Gene	SNPs	Allele (A1/A2)	Freq A1	Beta A1	Test Statistic	P-value	Clinical Impact (references)
<i>IFNG</i>	rs2430561	T/A	0.14	-10.02	-0.9861	0.3249	RSV adult seroconversion [24,25]
<i>TNF</i>	rs1800629	A/G	0.038	-9.539	-0.4631	0.6437	Severe influenza, Experi-RSV [25,26]
<i>IL-6</i>	rs1800795	G/C	0.098	7.457	0.6311	0.5285	Experi-RSV, adults/children [24,25]
<i>VDR</i>	rs2228570	G/A	0.40	-7.002	-0.9072	0.3651	RSV bronchiolitis, infants [27,28]
<i>MARCO</i>	rs1801275	G/A	0.36	-3.211	-0.4033	0.6871	RSV and wheezing, Chilean children [29]
<i>IFNL4</i>	rs12979860	A/G	0.23	25.49	2.884	0.00425 ^a	Lower age at hospital admission for bronchiolitis [30]
	rs4986790	G/A	0.020	40.08	1.448	0.1487	RSV in high risk infants [31]; severe RSV [10,32,33]
<i>IFNL3</i>	rs2243639	A/G	0.30	2.226	0.2791	0.7804	RSV in Chilean infants [34]
<i>ADRB2</i>	rs1800888	A/G	0.0054	90	1.713	0.08782	Asthma following severe RSV bronchiolitis[11]
		A/G	0.0018	92.8	1.022	0.3078	Asthma following severe RSV bronchiolitis[11]

264 ^aStatistically significant following Bonferroni adjustment for 11 statistical comparisons.

265

266 Discussion

267

268 RSV and other viral infections at a young age have previously been associated
269 with the later development of asthma [8,35–38]. In a study of American Indian children
270 living in the Great Plain geographic area of rural South Dakota, we observed many
271 similarities in the clinical characteristics of children with asthma as with prior studies,
272 including increased BMI [39,40], increased hospitalizations or a diagnosis of RSV [41],
273 higher levels of total serum IgE [42,43], and higher % eosinophils [44,45].

274 In the current study, we measured immunological response to prior RSV
275 infection, and find children with asthma to have lower levels of serum RSV-specific IgG
276 as compared to those without asthma. Surprisingly, our finding is specific to children
277 with asthma who were recruited during the winter months, when RSV is thought to be
278 circulating more broadly in the community and within households. Our findings suggest
279 that children with asthma have a reduced or varying immunological response to RSV
280 infection during the winter months as compared to children without asthma, which is not
281 present during the summer months. Future longitudinal and prospective studies are
282 warranted to determine the timing of exposure as it relates to IgG immunological
283 response in children with and without asthma, and to determine any relationship with
284 acute vs. long-term clinical outcomes.

285 Very few studies have examined RSV-specific IgG antibody levels in the context
286 of asthma and/or bronchial hyperreactivity for comparison to our current results. Backer
287 et al examined RSV-specific IgG among a randomly selected group of children between

288 7 and 16 years of age, but found no association with bronchial hyper-responsiveness to
289 histamine challenge [46]. In another study among 100 children less than 2 years of age
290 hospitalized for wheezing and followed for a median of 6 years, RSV-specific IgG
291 increased with age, but was not associated with asthma at any age [47]. In our cross-
292 sectional study, we found no significant association between RSV IgG concentration
293 and age in either our single or multi-variate analysis, however we did not perform any
294 longitudinal measurements within an individual. Although we are unaware of any recent
295 findings to date, the INSPIRE longitudinal study of RSV serology among nearly 2,000
296 infants may provide further information as to whether immunological response to RSV
297 infection is predictive of asthma or varies by season or age [48].

298 Lower RSV-specific IgG concentrations in asthma cases during the winter
299 months when RSV is thought to be circulating more broadly in the community was an
300 unanticipated finding (Fig 1). IgG antibodies typically peak within 3-4 weeks following
301 RSV infection and gradually decline over the next few months [49,50]. Thus, we
302 expected RSV IgG concentrations to be higher during times of recurring exposure
303 during the winter months for both asthma cases and controls. While the seasonality of
304 RSV infection is well accepted [50,51], we were unable to locate any independent
305 cohort surveillance information or cross-sectional serology surveys that recorded
306 seasonal timing of collection for comparison to our results. Thus, further efforts to
307 validate our findings and identify potential causal factors driving the observed interaction
308 between asthma and RSV season on IgG concentrations requires additional study.

309 Parents of children with asthma were more likely to report their child had been
310 previously diagnosed with RSV, and we observed a non-significant trend towards

311 increased rate of hospitalization due to RSV. While we do not have information on the
312 clinical course of RSV infection in our study participants beyond self-report, we
313 identified a shared genetic association that may provide additional insight as to whether
314 RSV-specific IgG concentrations are of any clinical relevance. The *IFNL4* variant we
315 found associated with RSV-specific IgG is a member of the interferon lambda family,
316 which is known to be involved in the immune response to viral infection. We identified
317 this as a candidate variant from Scagnolari et al [30], who found that individuals with the
318 AA genotype had a lower age at hospital admission due to RSV infection as compared
319 to infants carrying the GG/GA genotypes. In our study, Individuals with the AA genotype
320 had significantly higher levels of RSV-specific IgG as compared to individuals with the
321 GG genotype (Fig 2). Although this requires validation, our findings in combination with
322 Scagnolari et al. [30] suggest that individuals with two copies of the minor allele (AA
323 genotype) have a heightened immunological response to RSV infection that may lead to
324 increased hospitalization with RSV at a younger age. Prior studies have also found the
325 A allele associated with clinical presentation of allergic disease, including increased
326 rates of asthma, atopic dermatitis, and IgE-mediated food allergy for both the AG and
327 AA genotypes [52], but with a lower incidence of COVID19 [53]. Lastly, this variant has
328 been associated with varying response to pegylated interferon-alpha and ribavirin
329 treatment [54,55] and spontaneous clearance of hepatitis C infection [56,57], suggesting
330 the influence on viral infection is not exclusive to respiratory diseases.

331

332

333 **Figure 2. Median levels of RSV IgG concentration by genotype at rs12979860, an**
334 **intronic variant in *IFNL4* that is associated with RSV IgG concentration in**
335 **individuals with and without asthma (Table 6, p=0.0043). Individuals with two**
336 **copies of the minor A allele (AA genotype) have significantly higher levels of RSV**
337 **IgG as compared to individuals with two copies of the major G allele (GG**
338 **genotype) (t-test, p=0.01).**

339

340 We identified elevated total IgE concentrations (geometric mean 111.1 IU/ml) in
341 both asthma cases and controls overall, similar to that reported in Alaskan Native
342 children (geometric mean 122.1 kU/L) and in comparison to the Tucson Childhood
343 Respiratory Study (geometric mean 36.3 kU/L) [58]. A Korean cohort of children
344 between 12-13 years of age found a geometric mean total IgE of 90.6 kU/L and a 95
345 percentile of 991 kU/L [59]. High levels of IgE are consistent with a predominant
346 inflammatory asthma phenotype in our study, and similar to that reported by Redding et
347 al. in Alaskan Native children [58]. Elevated levels of total IgE suggest tendencies
348 toward immune hyperreactivity and asthma at the community level, in accordance with
349 reports of increased asthma prevalence in various other Indigenous communities
350 [60,61]. Consistent with there being a tradeoff in IgE vs. IgG production, and preferential
351 IgE production in Th2 cytokine environment [62,63], we indeed find lower levels of total
352 IgE in individuals with high RSV-specific IgG concentrations as compared to individuals
353 with low RSV concentrations (Table 2). However, total IgE was not predictive of RSV
354 IgG in our multivariable model that included asthma status (Table 4), and may indicate a

355 confounding correlation between asthma, % eosinophils, and serum total IgE on
356 immunological response to RSV that requires further study.

357 We find children with high RSV IgG concentration tended to live in larger
358 households, and had higher levels of cotinine levels indicating increased exposure to
359 second-hand tobacco smoke. These observations are consistent with prior studies [51]
360 that identified household crowding as a risk factor for RSV [64,65], including one study
361 among Alaskan Native children [66]. Prior studies have also found a relationship
362 between cotinine levels and increased risk of bronchiolitis and other complications of
363 RSV infection [67–69]. While we could not examine the effect of household size and
364 cotinine levels on clinical outcomes of RSV infection directly, our observation of higher
365 cotinine levels in children with high RSV IgG concentration is important given that
366 tobacco use and exposure is a serious public health concern in this community [70].

367

368 **Conclusion**

369

370 In this study we report high RSV-specific IgG concentrations among a case-control
371 study of asthma in American Indian children living in the Great Plains geographical area
372 of the U.S. RSV-specific IgG concentrations were lower in children with asthma as
373 compared to children without asthma during the winter months when RSV was likely
374 circulating at higher levels in the community. Factors contributing to this observation
375 include both genetic and environmental risk factors that require additional study.

376 **Acknowledgements**

377

378 We thank the study participants, Indian Health Service facilities, the Collaborative
379 Research Center for American Indian Health, the Colorado Anschutz Research
380 Genetics Organization (CARGO lab), and participating tribal community for their
381 extraordinary cooperation and involvement, which has been critical to the success of
382 this investigation. The views expressed in this paper are those of the authors and do not
383 necessarily reflect those of the Indian Health Service. Funding was provided by the
384 National Institute of Minority Health and Health Disparities, grant U54 MD008164.

385

386

387

388 **References**

- 389 1. Smyth RL, Openshaw PJ. Bronchiolitis *Lancet*. 2006;368: 312–322.
- 390 2. Dayan PS, Roskind CG, Levine DA, Kuppermann N. Controversies in the
391 management of children with bronchiolitis. *Clin Pediatr Emerg Med*. 2004;5: 41–53.
- 392 3. Simoes EAF, Carbonell-Estrany X. Impact of severe disease caused by respiratory
393 syncytial virus in children living in developed countries. *Pediatr Infect Dis J*.
394 2003;22: S13–S20.
- 395 4. Mansbach JM, Emond JA, Camargo CA Jr. Bronchiolitis in US emergency
396 departments 1992 to 2000: epidemiology and practice variation. *Pediatr Emerg
397 Care*. 2005;21: 242–247.
- 398 5. Holman RC, Curns AT, Cheek JE, Bresee JS, Singleton RJ, Carver K, et al.
399 Respiratory syncytial virus hospitalizations among American Indian and Alaska
400 Native infants and the general United States infant population. *Pediatrics*. 2004;114:
401 e437-44.
- 402 6. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F,
403 et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and
404 allergy at age 13. *Am J Respir Crit Care Med*. 2005;171: 137–141.
- 405 7. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al.
406 Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13
407 years. *Lancet*. 1999;354: 541–545.
- 408 8. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM.
409 Hospitalization for RSV bronchiolitis before 12 months of age and subsequent
410 asthma, atopy and wheeze: a longitudinal birth cohort study. *Pediatr Allergy
411 Immunol*. 2005;16: 386–392.
- 412 9. Gómez R, Colás C, Sebastián A, Arribas J. Respiratory repercussions in adults with
413 a history of infantile bronchiolitis. *Ann Allergy Asthma Immunol*. 2004;93: 447–451.
- 414 10. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, et al. Association between
415 common Toll-like receptor 4 mutations and severe respiratory syncytial virus
416 disease. *J Infect Dis*. 2004;189: 2057–2063.
- 417 11. Torgerson DG, Giri T, Druley TE, Zheng J, Huntsman S, Seibold MA, et al. Pooled
418 sequencing of candidate genes implicates rare variants in the development of
419 asthma following severe RSV bronchiolitis in infancy. *PLoS One*. 2015;10:
420 e0142649.
- 421 12. Gentile DA, Doyle WJ, Zeevi A, Howe-Adams J, Kapadia S, Trecki J, et al. Cytokine
422 gene polymorphisms moderate illness severity in infants with respiratory syncytial
423 virus infection. *Hum Immunol*. 2003;64: 338–344.

- 424 13. Hull J, Rowlands K, Lockhart E, Moore C, Sharland M, Kwiatkowski D. Variants of
425 the chemokine receptor CCR5 are associated with severe bronchiolitis caused by
426 respiratory syncytial virus. *J Infect Dis.* 2003;188: 904–907.
- 427 14. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al.
428 Determinants of asthma after severe respiratory syncytial virus bronchiolitis. *J*
429 *Allergy Clin Immunol.* 2012;130: 91-100.e3.
- 430 15. Agius G, Dindinaud G, Biggar RJ, Peyre R, Vaillant V, Ranger S, et al. An epidemic
431 of respiratory syncytial virus in elderly people: clinical and serological findings. *J*
432 *Med Virol.* 1990;30: 117–127.
- 433 16. Falsey AR, Walsh EE, Looney RJ, Kolassa JE, Formica MA, Criddle MC, et al.
434 Comparison of respiratory syncytial virus humoral immunity and response to
435 infection in young and elderly adults. *J Med Virol.* 1999;59: 221–226.
- 436 17. Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and
437 human metapneumovirus by reverse transcription polymerase chain reaction in
438 adults with and without respiratory illness. *J Clin Virol.* 2006;35: 46–50.
- 439 18. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. *BMJ.* 2019;366:
440 l5021.
- 441 19. Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, et al.
442 The epidemiology of medically attended respiratory syncytial virus in older adults in
443 the United States: A systematic review. *PLoS One.* 2017;12: e0182321.
- 444 20. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an
445 under-recognized problem. *Drugs Aging.* 2015;32: 261–269.
- 446 21. Schmidt H, Das A, Nam H, Yang A, Ison MG. Epidemiology and outcomes of
447 hospitalized adults with respiratory syncytial virus: A 6-year retrospective study.
448 *Influenza Other Respi Viruses.* 2019;13: 331–338.
- 449 22. Best LG, O’Leary RA, O’Leary MA, Yracheta JM. Humoral immune factors and
450 asthma among American Indian children: a case-control study. *BMC Pulm Med.*
451 2016;16: 93.
- 452 23. R Core Team. R: A language and environment for statistical computing. R
453 Foundation for Statistical Computing, Vienna, Austria. 2018. Available:
454 <https://www.R-project.org/>
- 455 24. Doyle WJ, Casselbrant ML, Li-Korotky H-S, Doyle APC, Lo C-Y, Turner R, et al.
456 The interleukin 6 -174 C/C genotype predicts greater rhinovirus illness. *J Infect Dis.*
457 2010;201: 199–206.
- 458 25. Gentile DA, Doyle WJ, Zeevi A, Piltcher O, Skoner DP. Cytokine gene
459 polymorphisms moderate responses to respiratory syncytial virus in adults. *Hum*
460 *Immunol.* 2003;64: 93–98.

- 461 26. Martinez-Ocaña J, Olivo-Diaz A, Salazar-Dominguez T, Reyes-Gordillo J, Tapia-
462 Aquino C, Martínez-Hernández F, et al. Plasma cytokine levels and cytokine gene
463 polymorphisms in Mexican patients during the influenza pandemic A(H1N1)pdm09.
464 *J Clin Virol.* 2013;58: 108–113.
- 465 27. McNally JD, Sampson M, Matheson LA, Hutton B, Little J. Vitamin D receptor
466 (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-
467 analysis. *Pediatr Pulmonol.* 2014;49: 790–799.
- 468 28. Laplana M, Royo JL, Fibla J. Vitamin D Receptor polymorphisms and risk of
469 enveloped virus infection: A meta-analysis. *Gene.* 2018;678: 384–394.
- 470 29. Tapia LI, Ampuero S, Palomino MA, Luchsinger V, Aguilar N, Ayarza E, et al.
471 Respiratory syncytial virus infection and recurrent wheezing in Chilean infants: a
472 genetic background? *Infect Genet Evol.* 2013;16: 54–61.
- 473 30. Scagnolari C, Midulla F, Riva E, Monteleone K, Solimini A, Bonci E, et al.
474 Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering
475 from bronchiolitis. *Virus Res.* 2012;165: 236–240.
- 476 31. Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztejn MB, Boukhvalova MS, et al.
477 Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus
478 infection in high-risk infants and young children. *J Immunol.* 2007;179: 3171–3177.
- 479 32. Tulic MK, Hurrelbrink RJ, Prêle CM, Laing IA, Upham JW, Le Souef P, et al. TLR4
480 polymorphisms mediate impaired responses to respiratory syncytial virus and
481 lipopolysaccharide. *J Immunol.* 2007;179: 132–140.
- 482 33. Zhou J, Zhang X, Liu S, Wang Z, Chen Q, Wu Y, et al. Genetic association of TLR4
483 Asp299Gly, TLR4 Thr399Ile, and CD14 C-159T polymorphisms with the risk of
484 severe RSV infection: a meta-analysis. *Influenza Other Respi Viruses.* 2016;10:
485 224–233.
- 486 34. Ampuero S, Luchsinger V, Tapia L, Palomino MA, Larrañaga CE. SP-A1, SP-A2
487 and SP-D gene polymorphisms in severe acute respiratory syncytial infection in
488 Chilean infants. *Infect Genet Evol.* 2011;11: 1368–1377.
- 489 35. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson
490 Children’s Respiratory Study: 1980 to present. *J Allergy Clin Immunol.* 2003;111:
491 661–75; quiz 676.
- 492 36. Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee W-M, et al.
493 Evidence for a causal relationship between allergic sensitization and rhinovirus
494 wheezing in early life. *Am J Respir Crit Care Med.* 2012;185: 281–285.
- 495 37. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV. Toward primary
496 prevention of asthma. Reviewing the evidence for early-life respiratory viral
497 infections as modifiable risk factors to prevent childhood asthma. *Am J Respir Crit
498 Care Med.* 2015;191: 34–44.

- 499 38. Lee KK, Hegele RG, Manfreda J, Wooldrage K, Becker AB, Ferguson AC, et al.
500 Relationship of early childhood viral exposures to respiratory symptoms, onset of
501 possible asthma and atopy in high risk children: the Canadian Asthma Primary
502 Prevention Study. *Pediatr Pulmonol.* 2007;42: 290–297.
- 503 39. Noonan CW, Brown BD, Bentley B, Conway K, Corcoran M, FourStar K, et al.
504 Variability in childhood asthma and body mass index across Northern Plains
505 American Indian communities. *J Asthma.* 2010;47: 496–500.
- 506 40. Dixon AE, Holguin F. Diet and metabolism in the evolution of asthma and obesity.
507 *Clin Chest Med.* 2019;40: 97–106.
- 508 41. Anderson J, Do LAH, Wurzel D, Quan Toh Z, Mulholland K, Pellicci DG, et al.
509 Severe respiratory syncytial virus disease in preterm infants: a case of innate
510 immaturity. *Thorax.* 2021; [thoraxjnl-2020-216291](https://doi.org/10.1136/thoraxjnl-2020-216291).
- 511 42. Hammad H, Lambrecht BN. The basic immunology of asthma. *Cell.* 2021;184:
512 2521–2522.
- 513 43. Lee Y, Quoc QL, Park HS. Biomarkers for severe asthma: Lessons from
514 longitudinal cohort studies. *Allergy Asthma Immunol Res.* 2021;13: 375–389.
- 515 44. Karakoc F, Remes ST, Martinez FD, Wright AL. The association between persistent
516 eosinophilia and asthma in childhood is independent of atopic status. *Clin Exp*
517 *Allergy.* 2002;32: 51–56.
- 518 45. Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US
519 perspective. *J Asthma Allergy.* 2014;7: 53–65.
- 520 46. Backer V, Ulrik CS, Bach-Mortensen N, Glikmann G, Mordhorst CH. Relationship
521 between viral antibodies and bronchial hyperresponsiveness in 495 unselected
522 children and adolescents. *Allergy.* 1993;48: 240–247.
- 523 47. Kotaniemi-Syrjänen A, Laatikainen A, Waris M, Reijonen TM, Vainionpää R, Korppi
524 M. Respiratory syncytial virus infection in children hospitalized for wheezing: virus-
525 specific studies from infancy to preschool years. *Acta Paediatr.* 2005;94: 159–165.
- 526 48. Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD, et al.
527 Objectives, design and enrollment results from the Infant Susceptibility to
528 Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE). *BMC*
529 *Pulm Med.* 2015;15: 45.
- 530 49. Welliver RC, Kaul TN, Putnam TI, Sun M, Riddlesberger K, Ogra PL. The antibody
531 response to primary and secondary infection with respiratory syncytial virus: kinetics
532 of class-specific responses. *J Pediatr.* 1980;96: 808–813.
- 533 50. Kutsaya A, Teros-Jaakkola T, Kakkola L, Toivonen L, Peltola V, Waris M, et al.
534 Prospective clinical and serological follow-up in early childhood reveals a high rate

- 535 of subclinical RSV infection and a relatively high reinfection rate within the first 3
536 years of life. *Epidemiol Infect.* 2016;144: 1622–1633.
- 537 51. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial
538 virus lower respiratory tract disease. *J Pediatr.* 2003;143: S118-26.
- 539 52. Chinnaswamy S, Wardzynska A, Pawelczyk M, Makowska J, Skaaby T, Mercader
540 JM, et al. A functional IFN- λ 4-generating DNA polymorphism could protect older
541 asthmatic women from aeroallergen sensitization and associate with clinical
542 features of asthma. *Sci Rep.* 2017;7: 10500.
- 543 53. Agwa SHA, Kamel MM, Elghazaly H, Abd Elsamee AM, Hafez H, Girgis SA, et al.
544 Association between interferon-lambda-3 rs12979860, TLL1 rs17047200 and DDR1
545 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2
546 patients. *Genes (Basel).* 2021;12: 830.
- 547 54. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B
548 is associated with response to chronic hepatitis C interferon-alpha and ribavirin
549 therapy. *Nat Genet.* 2009;41: 1100–1104.
- 550 55. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al.
551 Genome-wide association of IL28B with response to pegylated interferon-alpha and
552 ribavirin therapy for chronic hepatitis C. *Nat Genet.* 2009;41: 1105–1109.
- 553 56. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-
554 wide association study of spontaneous resolution of hepatitis C virus infection: data
555 from multiple cohorts. *Ann Intern Med.* 2013;158: 235–245.
- 556 57. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic
557 variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature.*
558 2009;461: 399–401.
- 559 58. Redding GJ, Singleton RJ, DeMain J, Bulkow LR, Martinez P, Lewis TC, et al.
560 Relationship between IgE and specific aeroallergen sensitivity in Alaskan native
561 children. *Ann Allergy Asthma Immunol.* 2006;97: 209–215.
- 562 59. Kim HY, Choi J, Ahn K, Hahm MI, Lee SY, Kim WK, et al. Reference values and
563 utility of serum total immunoglobulin E for predicting atopy and allergic diseases in
564 Korean schoolchildren. *J Korean Med Sci.* 2017;32: 803–809.
- 565 60. Upson DJ. Asthma in Navajo children: Striving for health equity. *Annals of the*
566 *American Thoracic Society.* American Thoracic Society; 2018. pp. 671–674.
- 567 61. Clark D, Gollub R, Green WF, Harvey N, Murphy SJ, Samet JM. Asthma in Jemez
568 Pueblo schoolchildren. *Am J Respir Crit Care Med.* 1995;151: 1625–1627.
- 569 62. Wesemann DR, Magee JM, Boboila C, Calado DP, Gallagher MP, Portuguese AJ,
570 et al. Immature B cells preferentially switch to IgE with increased direct S_{μ} to S_{ϵ}
571 recombination. *J Exp Med.* 2011;208: 2733–2746.


- 572 63. Scott-Taylor TH, Axinia S-C, Amin S, Pettengell R. Immunoglobulin G; structure and
573 functional implications of different subclass modifications in initiation and resolution
574 of allergy. *Immun Inflamm Dis*. 2018;6: 13–33.
- 575 64. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk
576 factors for respiratory syncytial virus-associated lower respiratory illnesses in the
577 first year of life. *Am J Epidemiol*. 1991;133: 1135–1151.
- 578 65. Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for
579 respiratory syncytial virus infection in premature infants born during two consecutive
580 seasons. *Pediatr Infect Dis J*. 2001;20: 874–879.
- 581 66. Bulkow LR, Singleton RJ, Karron RA, Harrison LH, Alaska RSV Study Group. Risk
582 factors for severe respiratory syncytial virus infection among Alaska native children.
583 *Pediatrics*. 2002;109: 210–216.
- 584 67. Gürkan F, Kiral A, Dağlı E, Karakoç F. The effect of passive smoking on the
585 development of respiratory syncytial virus bronchiolitis. *Eur J Epidemiol*. 2000;16:
586 465–468.
- 587 68. Sritippayawan S, Prapphal N, Wong P, Tosukhowong P, Samransamruajkit R,
588 Deerojanawong J. Environmental tobacco smoke exposure and respiratory
589 syncytial virus infection in young children hospitalized with acute lower respiratory
590 tract infection. *J Med Assoc Thai*. 2006;89: 2097–2103.
- 591 69. Maedel C, Kainz K, Frischer T, Reinweber M, Zacharasiewicz A. Increased severity
592 of respiratory syncytial virus airway infection due to passive smoke exposure.
593 *Pediatr Pulmonol*. 2018;53: 1299–1306.
- 594 70. O’Donald ER, Miller CP, O’Leary R, Ong J, Pacheco B, Foos K, et al. Active
595 smoking, secondhand smoke exposure and serum cotinine levels among Cheyenne
596 River Sioux communities in context of a Tribal Public Health Policy. *Tob Control*.
597 2020;29: 570–576.


598
599
600

601 **Supporting Information Captions**


602

603 **S1 Fig. Boxplot showing the distribution of Measles, Pertussis, and Tetanus titers**
604 **stratified by high (IgG>10 IU/mL, N=27) vs. low RSV IgG (IgG<10 IU/mL, N=16).**






Measles



Tetanus



Pertussis

